Rank Name of Executive Company Base Salary ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Stock Price 12/31/03 ($) Stock Price 12/31/04 ($) Percent Change Stock Price (%) Approx. Mkt. Cap. 12/31/04 ($M) 1 Kevin W. Sharer Amgen Inc. 1,302 1,098 15.6 61.79 64.15 3.8 80,829.00 2 Henri A. Termeer Genzyme Corp. 1,300 1,238 4.8 49.29 58.07 17.8 14,460.50 3 James C. Mullen (1) Biogen Idec Inc. 985 104 89.5 36.7 66.61 81.5 21,843.70 4 Frank

For The 237 CEOs In BioWorld's 264-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) Stock Price 12/31/04 Shares Out (M) Approx. Mkt. Cap. 12/31/04 ($M) 1 Kevin W. Sharer Amgen Inc. 1,302 3,662 4,964 64.15 1,260.00 80,829.00 2 Joseph A. Sorge Stratagene Corp. 771 2,442 3,212 7.75 22 170.7 3 Henri A. Termeer Genzyme Corp. 1,300 1,770 3,070 58.07 249 14,460.50 4 Frank Baldino Jr

Using the 264 proxy statements, we have gathered data on the compensation of executives responsible for legal affairs in the industry. The sample size of companies shrinks to 79 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number companies have no such position at all. The

Using the 264 proxy statements, we have gathered data on the compensation of executives responsible for business and/or corporate development in the industry. The sample size of companies shrinks to 72 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number companies have no

Using the 264 proxy statements, we have gathered data on the compensation of executives responsible for Research & Development (R&D) in the industry. The sample size of companies shrinks to 146 in the case of this position because many companies have no such position listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number companies have no such

Using the 264 proxy statements, we have gathered data on the compensation of Chief Financial Officers (CFOs) in the industry. The sample size of companies shrinks to 197 in the case of CFOs because many companies have no CFO listed among the top wage earners. (Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000.) A number of companies have no such position at all. The CFO listed for all

The data presented in these tables were obtained from proxy statements and annual reports of 264 biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC). Unless otherwise noted with symbols, companies had a fiscal year-end of Dec. 31, 2004. Numbered footnotes containing important details appear following this section. IMPORTANT NOTE: The CEO listed for 263 companies is the individual who held that title for the majority of the fiscal year reported. In

For Legal Executives Who Received A Full Year Of Salary, 75 Companies

For Business And Corporate Development Executives Who Received A Full Year Of Salary, 65 Companies

For R&D Executives Who Received A Full Year Of Salary, 146 Companies

For CFOs Who Received A Full Year Of Salary, 197 Companies

For The Public Biotechnology Companies In BioWorld's Survey Number of companies: 264 Total number of employees at the 264 companies: 108,743 Average number of employees: 412 Median number of employees: 126 Total Market Capitalization of the 264 companies on Dec. 31, 2004: $321.6 billion Average Market Capitalization per company on Dec. 31, 2004: $1.2 billion Median Market Capitalization per company on Dec. 31, 2004: $207.6 million Smallest Market Capitalization on Dec. 31, 2004: $761,160

For CEOs Who Received A Full Year Of Salary, 237 Companies

For CEOs Who Received A Full Year Of Salary, 237 Companies

For CEOs Who Received A Full Year Of Salary, 237 Companies

For CEOs Who Received A Full Year Of Salary, 237 Companies

For CEOs Who Received A Full Year Of Salary, 237 Companies

Managing Editor It wasn't a tremendous year for public firms in 2004, as witnessed by a mere 2.5 percent average gain in stock price, as shown by BioWorld's stock tracker, which is not market weighted. But biotech executives in general saw sizable gains, with four of the top five management positions recording compensation increases that outpaced the percentage growth of biotech stocks. Using Aon's eComp Data Services with financial data provided by Standard & Poors, BioWorld's team examined